Visual Abstract

Background: Continuous glucose monitoring (CGM) systems generate real-time information on blood glucose trends in PwD, providing regular feedback that may help inform care decisions. This study aimed to describe real-world CGM use and CGM-derived glucometrics in insulin-using PwD.

Methods: Data for adults (≥18 years) with T1D and T2D using insulin therapy and CGM were identified from Glooko’s cloud-based data storage and linked with Decision Resources Group™ Real-World Evidence repository (Jan 1, 2015-Jul 30, 2019). Summary statistics on 1-year aggregated CGM data and glucometrics are presented.

Results: Over one year, CGM data were uploaded on average 215.7 days (59%) for people with T1D (n = 4896) and 191.5 days (52%) for people with T2D (n = 582). Among people with T1D and T2D, time in range (TIR) was 59.9% and 62.6%, coefficient of variation (CV) was 36.0% and 30.7%, time above range (TAR; level 2) was 13.3% and 12.2%, and time below range (TBR; level 2) was 0.8% and 0.3%, respectively (Table1).

Conclusion: In this sample of PwD using insulin, level 2 TBR and CV were within the international consensus guideline recommendations, but TIR was below the recommended 70%, potentially driven by time spent in level 2 TAR. There is still an unmet clinical need for PwD to achieve guideline recommended targets; advancements in medications and technologies may help to achieve these goals.

Disclosure

M. Perez-nieves: Employee; Self; Eli Lilly and Company. R. Juneja: Employee; Self; Eli Lilly and Company. E. R. Hankosky: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. L. Fan: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company, Stock/Shareholder; Spouse/Partner; Eli Lilly and Company. F. Gelsey: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. E. L. Eby: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. T. J. Sims: Employee; Self; Eli Lilly and Company. E. Umeh: None. M. Betts: None. C. Lavallee: None.

Funding

Eli Lilly and Company

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.